Directorate Change

RNS Number : 3339U

ReNeuron Group plc

01 August 2022

 

ReNeuron Group plc

("ReNeuron" or the "Company" or the "Group")

Directorate Change

Catherine Isted appointed as Chief Executive Officer

ReNeuron Group plc (AIM: RENE),  a UK-based leader in stem cell derived exosome technologies, announces the appointment of Catherine Isted, ACMA, as Chief Executive Officer ("CEO"), effective 1 September 2022.

Ms. Isted joined the ReNeuron Board as Chief Financial Officer in October 2021. Following the departure of the former CEO in February this year, Ms. Isted has worked closely with the Executive Management team, led by Iain Ross, to refocus the business around the Group's differentiated exosomes delivery platform.

Ms. Isted is an experienced strategic finance professional and chartered management accountant with c.25 years' experience across the Healthcare industry. This includes 12 years at partner level in two leading Healthcare banking teams undertaking multiple Initial Public Offerings and follow-on fundraisings. Within the Healthcare industry, prior to joining ReNeuron, Ms. Isted has also held various in-house financial and strategic roles spanning Corporate Development, Investor Relations and Financial Planning and Analysis.

Ms. Isted joined ReNeuron from Oxford Biomedica plc, a global leading cell and gene therapy company, where she was instrumental in raising in excess of £110 million and supporting potential board level strategic opportunities. She has also held senior research analyst and equity sales positions in the Healthcare teams at Morgan Stanley, ABN AMRO, Nomura and Peel Hunt. Ms. Isted holds a 1st Class chemistry degree along with experience as a bench scientist, before moving into finance and training as an accountant at Merck.

Iain Ross, Chairman, commented: "Over the last six months and under my leadership, Catherine has worked with the executive team to refine the strategic and operational focus of the Company. She has shown herself to be an excellent candidate for the role and consequently, against external competition, the Board has taken the decision to appoint Catherine as the new CEO. I will revert to being non-executive Chairman after a period during which I support the transition. We intend to announce further organisational changes in due course."

Catherine Isted, incoming Chief Executive Officer, commented : "I feel honoured and grateful for the confidence that Iain and the Board have put in me to lead ReNeuron as we look to build a truly world class drug delivery platform for the next generation of targeted medicines. ReNeuron has not only great science but also great people and together that is a powerful combination. I look forward to, and remain committed to, continuing to work tirelessly to realise the full potential of ReNeuron for the benefit of all of the Company's stakeholders."

ENDS

The person responsible for arranging for the release of this announcement on behalf of the Company is Iain Ross, Chairman.

Contacts:

ReNeuron Group plc	www.reneuron.com/investors
Iain Ross, Chairman	Via Walbrook PR
John Hawkins, Company Secretary
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking)	[phone]
Allenby Capital Limited (Joint Broker)	[phone]
James Reeve / George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)	[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron is a UK based Proprietary Stem Cell based Exosome Technologies company, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary Exosome Technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Group has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-licence both these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit  www.reneuron.com

 

END

 

 

BOABLGDRCBDDGDC